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samples in age groups highlighted a 
relative homogeneity throughout the 
corresponding cohort.
Our study shows that PARV4 in-
fection is readily detectable in French 
blood donors. Prevalence results us-
ing probe PARV4-O were comparable 
to those obtained in previous studies 
involving healthy persons originating 
from various countries (4–6). Con-
versely, the high prevalence obtained 
by using probe PARV4-N was unex-
pected because only 1 study demon-
strated a higher value (45.7%) after 
the investigation of PARV4 DNA in 
bone marrow aspirates of AIDS pa-
tients from Italy (9).
This  ﬁ   nding suggests a larger 
dispersion of PARV4 than expected 
initially in the general population and 
highlights the need for improvement 
in detection systems directed toward 
PARV4 DNA, particularly by inter-
laboratory collaborations, in direct 
connection with studies investigat-
ing PARV4 genetic diversity. These 
considerations are consistent with the 
recent description of a new PARV4 
genogroup in humans and character-
ization of highly divergent variants in 
bovine and porcine species (10). In ad-
dition, such data raise the question of 
the consequent persistence of PARV4 
infection in healthy persons. Future 
studies need to explore both disper-
sion and potential clinical impact of 
PARV4 on infected hosts.  
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Otomastoiditis 
Caused by 
Mycobacterium 
abscessus, 
the Netherlands
To the Editor: Nontuberculous 
mycobacteria (NTM) are increasingly 
recognized as human pathogens (1). 
Otomastoiditis is a rare extrapulmo-
nary NTM disease type ﬁ  rst described 
in 1976; Mycobacterium chelonae–M. 
abscessus group bacteria, which are 
rapidly growing NTM, are the most 
frequent causative agents and the dis-
ease mostly affects children (1–3). 
In the Netherlands, M. chelonae–M. 
abscessus group isolates have been 
reported from the otologic samples of 
an average of 2 patients annually since 
2006, as compared to 6 patients in the 
preceding 10 years. This emergence 
is not a likely result of improved 
laboratory facilities or awareness in 
clinicians because liquid culture and 
molecular identiﬁ  cation  techniques 
predate the rise in notiﬁ  cation  and 
Dutch guidelines advise against per-
forming cultures for chronic otorrhea.
We identiﬁ  ed 10 patients from the 
national reference laboratory database 
with otologic samples yielding M. 
chelonae–M. abscessus group bacteria 
during January 1995–June 2007. We 
resubjected these isolates to molecular 
identiﬁ  cation by rpoB gene sequenc-
ing (4) and performed a medical ﬁ  le 
review.
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The  rpoB gene sequencing 
showed that M. abscessus was the 
causative agent in all 10 cases; M. 
abscessus seems to have a predilec-
tion to cause otomastoiditis. Closely 
related M. bolletii and M. massiliense 
(4) were not found. Early reports iden-
tiﬁ  ed M. fortuitum or M. chelonae as 
causative agents, which may be be-
cause the taxonomy of the rapidly 
growing NTM has long been debated 
(2,4–7); many of these agents may 
have, in fact, been M. abscessus. All 
primary isolates were found suscep-
tible to clarithromycin and resistant 
to ﬂ  uoroquinolones and aminoglyco-
sides in our agar dilution method (8), 
which is not the recommended method 
for rapidly growing NTM (1). Two pa-
tients acquired clarithromycin resis-
tance during treatment. 
Clinical data are summarized 
in the online Appendix Table (avail-
able from http://www.cdc.gov/EID/
content/16/1/167-appT.htm) and match 
those of previous studies (3,5,6). All 
patients had a history of ear infections 
and tympanostomy tube placement, 
previously associated with NTM dis-
ease (7). Nine patients had used ototo-
pical medication, including quinolone 
antimicrobial agents (n = 5), steroids, 
aminoglycosides (n = 2), or both (n = 
2). Clinical signs were nonspeciﬁ  c, 
with persistent tympanic membrane 
perforation, chronic painless otorrhea 
resistant to antimicrobial drug therapy, 
and hearing loss.
The fact that this disease primar-
ily affects children, with a mean age 
of 6 years, may be related to age-spe-
ciﬁ   c environmental exposures, e.g., 
playing in sand pits or swimming (9). 
Two patients with M. abscessus oto-
mastoiditis are siblings (patients 5 
and 6); a clonal relationship between 
the causative bacteria is possible and 
should be investigated by molecular 
typing tools.
Primary isolates were from bi-
opsy material (n = 5) or otorrhea ﬂ  uid 
(n = 5) and were positive for acid-
fast bacilli by direct microscopy for 9 
patients. Five patients had a computed 
tomography (CT) scan performed, 
which showed ﬂ  uid in the mastoid (n 
= 4), bone erosion of the mastoid (n = 
2), and mucosal swelling (all); the on-
line Appendix Figure (available from 
www.cdc.gov/EID/content/16/1/167-
appF.htm) displays typical ﬁ  ndings.
The mean interval between ﬁ  rst 
symptoms and diagnosis of M. ab-
scessus otomastoiditis was 155 days 
for (range 14–360 days). Otorrhea un-
responsive to antimicrobial drug ther-
apy should raise a clinical suspicion of 
NTM otomastoiditis (3), especially in 
patients with bone destruction visible 
on CT images. In patients with otor-
rhea unresponsive to antimicrobial 
drug therapy, routine CT scanning and 
Mycobacterium spp. cultures, pref-
erably from tissue biopsies (1), may 
reduce diagnostic delay and prevent 
further damage.
Patients with M. abscessus oto-
mastoiditis received drug treatment 
for a mean duration of 3 months (range 
28–150 days) and 1.8 episodes of sur-
gery. Five patients with M. abscessus 
otomastoiditis received clarithromy-
cin monotherapy, 5 received multi-
drug therapy with ﬂ  uoroquinolones (n 
= 3), ﬂ  uoroquinolones, rifampin, and 
ethambutol (n = 1), or meropenem (n 
= 1 (online Appendix Table).
Complications of surgery com-
prised delayed wound healing (n = 4) 
and  ﬁ  stula formation (n = 2; online 
Appendix Table). Two patients un-
derwent incus removal and later chain 
reconstruction surgery (patients 7 and 
8). In 1 patient, the infection spread 
and caused culture-proven cervical 
lymphadenitis, a retroauricular ab-
scess, ﬁ  stula, and facial nerve palsy.
Eight patients were eventually 
cured, deﬁ   ned by symptomatic im-
provement and in some cases con-
ﬁ  rmed by negative cultures. Two pa-
tients were still receiving treatment at 
the time of data collection. Five pa-
tients had persistent conductive hear-
ing loss after treatment (42%; range 
30–80 dB; online Appendix Table).
American Thoracic Society guide-
lines for treatment of soft tissue and 
bone infections caused by M. absces-
sus advocate 4–6 months of therapy 
with a macrolide, an aminoglycoside 
and cefoxitin or a carbapenem, based 
on in vitro drug susceptibility test re-
sults, combined with surgical debri-
dement when possible (1). Treatment 
regimens in this study deviated in 
duration and content; clarithromycin 
monotherapy is likely to invoke re-
sistance (1) and no evidence supports 
ﬂ   uoroquinolone use (1). Moreover, 
use of parenteral agents was limited; 
its reasoning was not generally cap-
tured during ﬁ  le review.
M. abscessus otomastoiditis is a 
serious, potentially emerging condition 
that affects children who have had pre-
vious infections, tympanostomy tubes, 
and ototopical antimicrobial drug or 
steroid use in the Netherlands. The di-
agnostic delay and treatment regimens 
warrant improvement to prevent deteri-
oration, additional episodes of surgery, 
acquired drug resistance, and to prevent 
or limit permanent hearing loss.
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Diseases Tracked 
by Using Google 
Trends, Spain
To the Editor: We read the article 
by Pelat et al. (1) with great interest 
and decided to explore whether this 
tool could be applicable for non-Eng-
lish and non-French speaking coun-
tries and, more speciﬁ  cally, for Spain. 
We compared the Google queries re-
lated to inﬂ  uenza-like illness (ILI) and 
chickenpox described by Pelat et al. 
(1), and constructed additional queries 
with symptoms and conditions fre-
quently associated with ILI.
The weekly queries from Janu-
ary 2004 through February 2009 were 
downloaded from Google Insights for 
Search (2). We studied the correlation 
(Spearman  ρ) of these queries with 
the data from the national reporting of 
notiﬁ  able diseases, available from the 
Spanish National Epidemiology Cen-
ter website (3), assuming a maximum 
difference of 4 weeks.
The queries for gripe (Spanish for 
inﬂ  uenza) showed a maximum corre-
lation (ρ = 0.70) 2 weeks before the 
declared ILI (DILI). When excluding 
the terms for aviar (avian) and va-
cuna (vaccine), the correlation peak 
(ρ = 0.81) was likewise observable 
2 weeks before the DILI. The maxi-
mum correlation observed for symp-
tom queries was for tos (Spanish for 
cough) 2 weeks before the DILI (ρ = 
0.74); for conditions associated with 
inﬂ  uenza the correlation was for neu-
monía (Spanish for pneumonia, ac-
cented or unaccented) 2 weeks after 
the DILI (ρ = 0.84). The queries for 
varicela (Spanish for chickenpox) 
showed a maximum correlation (ρ = 
0.96) 1 week after the declared illness, 
as observed by Pelat et al (1).
In conclusion, our study points 
out the utility of Internet queries for 
the surveillance of ILI and chicken-
pox in Spain. In the case of ILI, this 
information can be used as an early 
warning tool used complementarily to 
standard surveillance systems. More 
detailed studies are necessary regard-
ing the usefulness and limitations of 
this tool in Spain, as well as in other 
contexts.
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Letters
Letters commenting on recent articles 
as well as letters reporting cases, 
outbreaks, or original research are 
welcome. Letters commenting on ar-
ticles should contain no more than 
300 words and 5 references; they are 
more likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words and 
10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.